- Home
- / Stallergenes Greer
Stallergenes Greer
Revenue
€277.1 M
FY, 2018
Stallergenes Greer Summary
Company Summary
- Overview
- Stallergenes Greer International is a global biopharmaceutical company dedicated to the research and development of innovative treatments for allergies.
- Type
- Private
- Status
- Active
- Founded
- 2015
- HQ
- London, GB | view all locations
- Cybersecurity rating
- ESG rating
- Sectors
Table of Contents
Key People
Amer Jaber, Executive Vice President, Operations Europe
Tibor Nemes, Executive Vice President, Head of Americas
Jérôme Tilly, Senior Vice President, Human resources
LocationsView all
22 locations detected
London, England HQ
United Kingdom
Boston, MA
United States
179 Lincoln St #303
Lenoir, NC
United States
639 Nuway Cir
Warriewood, NSW
Australia
Suite 2408/4 Daydream St
Wien, Wien
Austria
Mariahilfer Str. 103
Wien, Wien
Austria
Mariahilfer Str. 74A/top 14
Stallergenes Greer Financials
Summary Financials
- Revenue (FY, 2018)
- €277.1M
- Gross profit (FY, 2018)
- €201.5M
- Net income (FY, 2018)
- €12.8M
- Cash (FY, 2018)
- €73.9M
- EBIT (FY, 2018)
- €17.6M